Terho Heikkinen
Professor of Paediatrics, MD, PhD
teheikki@utu.fi |
Paediatric infectious diseases; respiratory infections; respiratory viruses; vaccinations; influenza; respiratory syncytial virus; otitis media
Respiratory infections in children; RESCEU (EU/IMI-funded project 2017-2021); INFORM study
Professor Terho Heikkinen graduated from the Medical School at the
University of Turku in 1984, where he also specialized in Paediatrics and Paediatric
Infectious Diseases. He defended his thesis on Development and prevention of acute
otitis media in children in 1994. Having received the European Society for
Paediatric Infectious Diseases Fellowship Award, he worked in 1996-1998 as
a post-doc Research Fellow at the University of Texas Medical Branch at
Galveston, USA. Subsequently, he worked as a Senior Clinical Researcher and
Clinical Lecturer at the Department of Paediatrics, University of Turku. Since
2016, he has been Professor of Paediatrics at
the Faculty of Medicine, University of Turku.
During the years, Terho Heikkinen has served as the chairman or a board member
of several international and domestic societies in the field of paediatric
infectious diseases, including the President of the World Society for
Pediatric Infectious Diseases. He is currently a board member of the European Scientific
Working Group on Influenza (ESWI), a scientific advisory board and executive committee member of the global Respiratory Syncytial Virus Network (ReSViNET), and the chairman of the Nordic Research Network for Paediatric Infectious Diseases (NORDPID).
Terho Heikkinen´s major research interest lies in respiratory infections,
especially those caused by influenza or respiratory syncytial viruses. In year 2000, he founded his own research group and initiated a long-term research project on respiratory virus infections in children,
including the etiology, epidemiology, diagnosis, treatment, prevention, and
overall societal impact of these infections and their complications.
Terho Heikkinen has been
actively involved in international research collaboration. In 2014, he was a founding member of ReSViNET, a global respiratory syncytial virus research network.
He is also a principal investigator in RESCEU (Respiratory syncytial virus
consortium in Europe) that in 2017 received 5-year EU/IMI funding for research
on the burden of respiratory syncytial virus infections in Europe. He was also a founding member of the Nordic Research Network for Paediatric Infectious Diseases (NORDPID) that was established in 2018.
Since 1999, Terho Heikkinen has worked as a full-time
teacher of paediatrics at the Department of Paediatrics, University of Turku. He
is also responsible for the organization of the biannual International Course
of Paediatrics & Adolescent Medicine for international Erasmus students. He
has given 188 invited lectures at various international and domestic academic
meetings.
- Characterising the asynchronous resurgence of common respiratory viruses following the COVID-19 pandemic (2025)
- Nature Communications
- Estimation of respiratory syncytial virus-associated hospital admissions in five European countries: a modelling study (2025)
- Lancet regional health - Europe
- Respiratory syncytial virus hospitalisation burden in children below 18 years in six European countries (2016-2023) pre-and post-COVID-19 pandemic (2025)
- International Journal of Infectious Diseases
- Twenty-five years of palivizumab: a global historic review of its impact on the burden of respiratory syncytial virus disease in childrenThe genomic evolutionary dynamics and global circulation patterns of respiratory syncytial virus (2025)
- Expert Review of Anti-infective TherapyNature Communications
- Effectiveness of immunisation products against medically attended respiratory syncytial virus infection: generic protocol for a test-negative case-control studyThe respiratory microbiome is linked to the severity of RSV infections and the persistence of symptoms in children (2024)
- Journal of Infectious DiseasesCell Reports Medicine
- Effectiveness of vaccines and monoclonal antibodies against respiratory syncytial virus: Generic protocol for register-based cohort study (2024)
- Journal of Infectious Diseases
- Global disease burden of and risk factors for acute lower respiratory infections caused by respiratory syncytial virus in preterm infants and young children in 2019: a systematic review and meta-analysis of aggregated and individual participant data (2024)
- Lancet
- Inconsistent Increase in Age at Respiratory Syncytial Virus Hospitalization of Children Aged <2 Years During the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic: A Retrospective Multicenter Study in 4 European Countries (2024)
- Journal of Infectious Diseases
- Mikrobiologia, immunologia ja infektiosairaudet. Kirja 2, Immunologia (2024) Heikkinen, Terho; Järvinen, Asko; Meri, Seppo; Vuopio, Jaana
- Nirsevimabi tulee ottaa laajempaan käyttöön (2024)
- Lääkärilehti
- Respiratory Syncytial Virus–Associated Hospital Admissions by Deprivation Levels Among Children and Adults in Scotland (2024)
- Journal of Infectious Diseases
- Respiratory Syncytial Virus–Associated Hospitalization in Adults With Comorbidities in 2 European Countries: A Modeling Study (2024)
- Journal of Infectious Diseases
- Respiratory Syncytial Virus-Associated Hospitalizations in Children: A 10-Year Population-Based Analysis in Finland, 2008–2018 (2024)
- Pediatrics
- Substantial Burden of Nonmedically Attended RSV Infection in Healthy-Term Infants : An International Prospective Birth Cohort Study (2024)
- Journal of Infectious Diseases
- (2024)
- (2024)
- Uudet keinot käyttöön RSV:n ehkäisyssä (2024)
- Duodecim
- Burden of Respiratory Syncytial Virus in the European Union: estimation of RSV-associated hospitalizations in children under 5 years (2023)
- Journal of Infectious Diseases
- Changes in the global hospitalisation burden of respiratory syncytial virus in young children during the COVID-19 pandemic: a systematic analysis (2023)
- Lancet Infectious Diseases
- Cost-effectiveness of monoclonal antibody and maternal immunization against respiratory syncytial virus (RSV) in infants: Evaluation for six European countries (2023)
- Vaccine